WO2015100929A1 - Method for constructing eukaryotic gene knockout library by using crispr/cas9 system - Google Patents
Method for constructing eukaryotic gene knockout library by using crispr/cas9 system Download PDFInfo
- Publication number
- WO2015100929A1 WO2015100929A1 PCT/CN2014/078586 CN2014078586W WO2015100929A1 WO 2015100929 A1 WO2015100929 A1 WO 2015100929A1 CN 2014078586 W CN2014078586 W CN 2014078586W WO 2015100929 A1 WO2015100929 A1 WO 2015100929A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgrna
- library
- cells
- sequence
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Definitions
- the present invention relates to the field of genomics and genetic engineering, and in particular to a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system. Background technique
- Gene knockout a technical means of destroying or altering the function of a gene by destroying or altering its gene sequence.
- Commonly used gene knockout methods include: zinc finger nucleases (ZFNs) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011), transcription factor activating factor nucleases (TALEN) (Miller et Al., 2011; Wood et al., 2011; Zhang et al., 2011), and recently discovered the second class of adaptive immune system CRISPER/Cas9 systems for prokaryotes (Cong et al., 2013; Mali et al., 2013) and so on.
- ZFNs zinc finger nucleases
- TALEN transcription factor activating factor nucleases
- the CRISPER/Cas9 system was originally used by the bacterial immune system to protect against foreign viruses or plasmids.
- Cas9 endonuclease cleaves double-stranded DNA under the guidance of sgRNA, causing genomic double-strand breaks, resulting in repair errors (base deletion or insertion) using the instability of cellular genome repair. It may cause loss of gene function and achieve the purpose of gene knockout.
- lentiviral vector-based RNA interference libraries Prior to the generation of knockout libraries, lentiviral vector-based RNA interference libraries became an effective tool for studying gene function. Due to their convenience, shRNA libraries have been widely used in recent years. These shRNA interference libraries are used to search for genes related to a specific function. The methods are summarized as follows: packaging viruses using a lentiviral packaging system; infecting target cells with viruses; using antibiotics or streams The cytometer enriches the cells infected and integrated with the virus, that is, the library cells; screens the cells having the function-related traits to be studied; extracts the genomic DNA of the selected cells and the untreated library cells; and amplifies the shRNA integration by PCR Sections or amplified shRNA library design barcodes, using deep sequencing technology for sequencing; matching the sequencing results with known shRNA; analyzing and calculating the degree of enrichment of different shRNAs, thereby further studying the highly enriched The function of the gene corresponding to shRNA.
- the shRNA library is not a knockout library and can only partially silence gene expression.
- some knockout libraries have been reported, particularly KBM7 cells, which are part of haploid cells, can be used to construct knockout libraries, but their stability and efficiency are problematic, and the system is limited to specific cell lines, The scope of application is limited. Summary of the invention The present invention aims to construct a eukaryotic gene knockout library, and a method for efficiently and rapidly identifying gene functions based on functional screening, and can achieve large-scale, high-throughput and coverage of whole genomes.
- the present invention first provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Ca S 9 system, comprising the steps of:
- sgRNA action site 5'-G-Nx-NGG-3' design and synthesize sgRNA monomer targeting the above-mentioned site of action, designing for the same sgRNA action site
- Two sgRNA monomers the sequence of which is forward monomer: 5'-ACCG-Nx-3', reverse monomer: 5'-AAAC-N' ⁇ -3', where N' X is the inverse of Nx
- N and N' represent a base, T, G or C;
- the PLL3.7 vector is ligated to replace the U6 promoter on the original vector, and the constructed vector and ii are obtained. Mix the mixture, add fisfil restriction endonuclease and T4 ligase, 37 ° C for 5 min, 16 C 5 min, repeat 10 cycles;
- step 4 Inoculate the eukaryotic cell line constructed in step 1) with the harvested virus solution at 0.01 ⁇ MOI ⁇ 0.3. After the cells are cultured, the cells with green fluorescence are sorted by flow cytometry to obtain the eukaryotic gene. Knockout cell library.
- the eukaryotic host cell in the step 1) includes, but is not limited to, HEK293T, HT1080, HeLa cells and the like.
- the flexible Linker sequence described in step 1) is p2A:
- the present invention also provides a library of eukaryotic gene knockout cells constructed by the above method.
- the present invention further provides a method for studying gene function, extracting genomic DNA of a cell based on the eukaryotic gene knockout cell library, designing a primer, PCR-amplifying a DNA fragment containing the sgRNA sequence, and using deep sequencing technology (Deep Sequencing)
- the amplified product was sequenced, the sequencing result was analyzed, and the function of the gene corresponding to the sgRNA was determined by comparing the degree of enrichment of the sgRNA.
- the primer sequence is a forward primer: 5'-TATCTTGTGGAAAGGACGAAAC ACC-3 ', reverse primer: 5'-AATACGGTTATCCACGCGGC-3'.
- the number of cycles of amplification is 25-30.
- the method for constructing the eukaryotic gene knockout library provided by the present invention firstly expresses the gene encoding the Cas9 and OCT1 proteins in a eukaryotic cell line, selects a cell line stably expressing Cas9, and performs library construction and function screening. Its greatest advantage is that this method can be applied to most eukaryotic cell lines, independent of specific cell lines. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor costs caused by single preparation of knockout cells. DRAWINGS
- Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention.
- Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
- Fig. 3 shows that the system involved in the method of the present invention can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
- Figure 4 is a ranking of candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention; wherein: a: heat map shows side sgRNA binding deep sequencing analysis of sputum toxin and diphtheria toxin host Summary of gene results; b and c: sgRNAs enriched after anthrax toxin and diphtheria toxin screening, and the genes they target. The degree of enrichment of sgRNA is obtained by dividing the normalized average experimental reading by the control value. The chart values represent the average of the three values, arranged from high to low. Red markers indicate sgRNAs as well as known toxin-associated host genes. d and e: The T7E1 digestion method indicates the insertion or deletion mutation rate (indels) of a specific DNA sequence caused by various sgRNAs of AN XR1(d) or HBEGF(e).
- a heat map shows side sgRNA binding
- Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention is highly resistant to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
- Fig. 6 shows that the PECR gene of the anthrax toxin chimeric toxin in the first embodiment of the present invention has a certain resistance to the anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
- Figure 7 is a graph showing that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.
- Figure 8 is a schematic view showing the structure of the vector pOCTl-2A-Cas9-IRES-BSD in the present invention. detailed description
- Example 1 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with anthrax toxin cytotoxicity
- 293T cells were plated at a density of 3 ⁇ 10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
- PEI polyethylenimine
- the selected cells were plated at a density of 1 ⁇ 10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed.
- the PA protein was 70 ng/mL and the LFn-DTA protein was 50 ng/mL. After culturing for 48 hours, replace the fresh medium and repeat the process three times;
- genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification.
- the total amount of genomic DNA of each group as a template was 8 ⁇ ⁇ , PCR was performed for 26 cycles, and PCR was performed. product;
- the purified PCR products were sequenced using HiSeq2500 and ranked according to the abundance changes of sgRNA before and after toxin treatment, and the top three were all known receptors for anthrax toxin. And to find a new gene PECR that may be related to the toxicity of anthrax toxin.
- Example 2 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with diphtheria toxin cytotoxicity
- 293T cells were plated at a density of 3 ⁇ 10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
- PEI polyethylenimine
- the selected cells were plated at a density of 1 ⁇ 10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. DT protein 7.5 ng/mL was added to the culture medium, cultured for 48 hours, and the fresh culture solution was replaced. Repeat this process three times; 7. Extract genomic DNA and amplify
- genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification.
- the total amount of genomic DNA of each group as a template was 8 ⁇ ⁇ , PCR was performed for 26 cycles, and PCR was performed. product;
- the purified PCR product was sequenced using HiSeq 2500 and sorted according to the abundance change of sgRNA before and after toxin treatment, and the first place was the known receptor for diphtheria toxin.
- Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention.
- Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
- Fig. 3 shows that the system involved in the coding method can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
- Fig. 4 is a result of sorting candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention.
- Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has strong resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
- Fig. 6 is a diagram showing that the PECR gene in the candidate gene after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has certain resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
- Fig. 7 shows that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.
- the present invention provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system, and the greatest advantage of the method is that the method can be applied to most eukaryotic cell lines without being affected by a specific cell line. limit.
- the functional screening has a high positive rate and a low background value.
- the large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor cost caused by single preparation of knockout cells. references
Landscapes
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
利用 CRISPR/Cas9系统构建真核基因敲除文库的方法 技术领域 Method for constructing eukaryotic gene knockout library using CRISPR/Cas9 system
本发明涉及基因体学及基因工程领域, 具体地说, 涉及一种利用 CRISPR/Cas9系统构建真核基因敲除文库的方法。 背景技术 The present invention relates to the field of genomics and genetic engineering, and in particular to a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system. Background technique
基因敲除, 即针对某个特定的基因, 通过破坏或改变其基因序列令其功能 丧失的一种技术手段。 常用的基因敲除方法包括: 锌指核酸酶(ZFNs ) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011)、 类转录因子活化因子核 酸酶 ( TALEN ) (Miller et al., 2011; Wood et al., 2011; Zhang et al., 2011), 以及最 近发现的原核生物第二类适应性免疫系统 CRISPER/Cas9系统 (Cong et al., 2013; Mali et al., 2013)等。 CRISPER/Cas9系统原本被细菌免疫系统用来抵御外源病毒 或质粒。在第二类 CRISPER系统中, Cas9核酸内切酶在 sgRNA的引导下切割双链 DNA, 造成基因组双链断裂, 利用细胞基因组修复的不稳定性产生修复错误(碱 基的缺失或插入), 从而可能造成基因功能的丧失, 实现基因敲除的目的。 Gene knockout, a technical means of destroying or altering the function of a gene by destroying or altering its gene sequence. Commonly used gene knockout methods include: zinc finger nucleases (ZFNs) (Miller et al., 2007; Porteus and Baltimore, 2003; Wood et al., 2011), transcription factor activating factor nucleases (TALEN) (Miller et Al., 2011; Wood et al., 2011; Zhang et al., 2011), and recently discovered the second class of adaptive immune system CRISPER/Cas9 systems for prokaryotes (Cong et al., 2013; Mali et al., 2013) and so on. The CRISPER/Cas9 system was originally used by the bacterial immune system to protect against foreign viruses or plasmids. In the second type of CRISPR system, Cas9 endonuclease cleaves double-stranded DNA under the guidance of sgRNA, causing genomic double-strand breaks, resulting in repair errors (base deletion or insertion) using the instability of cellular genome repair. It may cause loss of gene function and achieve the purpose of gene knockout.
在基因敲除文库产生之前, 基于慢病毒载体的 RNA干扰文库成为研究基因 功能的有效工具。 由于其便利性, 近年来 shRNA文库得以普遍应用, 利用这类 shRNA干扰文库寻找与某特定功能相关的基因, 方法概括如下: 使用慢病毒包装 系统包装病毒; 使用病毒感染靶细胞; 利用抗生素或流式细胞仪富集病毒感染并 整合的细胞, 即为文库细胞; 筛选具有待研究功能相关性状的细胞; 提取筛选出 的细胞和未作处理的文库细胞的基因组 DNA;通过 PCR扩增 shRNA整合的区段或 扩增 shRNA文库设计时自带的条码(barcodes ), 利用深度测序技术进行测序; 将 测序结果与已知 shRNA进行匹配; 分析计算不同 shRNA的富集程度, 从而进一步 研究被高度富集的 shRNA所对应基因的功能。 Prior to the generation of knockout libraries, lentiviral vector-based RNA interference libraries became an effective tool for studying gene function. Due to their convenience, shRNA libraries have been widely used in recent years. These shRNA interference libraries are used to search for genes related to a specific function. The methods are summarized as follows: packaging viruses using a lentiviral packaging system; infecting target cells with viruses; using antibiotics or streams The cytometer enriches the cells infected and integrated with the virus, that is, the library cells; screens the cells having the function-related traits to be studied; extracts the genomic DNA of the selected cells and the untreated library cells; and amplifies the shRNA integration by PCR Sections or amplified shRNA library design barcodes, using deep sequencing technology for sequencing; matching the sequencing results with known shRNA; analyzing and calculating the degree of enrichment of different shRNAs, thereby further studying the highly enriched The function of the gene corresponding to shRNA.
然而, shRNA文库并不是基因敲除文库, 只能部分沉默基因表达。 存在许 多不足, 例如对特定基因表达的影响往往不能导致表型的改变; 可能错误地抑制 不相关基因表达等。 虽然有一些基因敲除文库已被报道, 特别是 KBM7细胞, 它 是部分单倍体细胞, 可用于构建敲除文库, 但其稳定性和效率都存在问题, 而且 该系统局限于特定细胞系, 应用范围受限。 发明内容 本发明旨在构建真核基因敲除文库, 以及基于功能性筛选高效快速鉴定基 因功能的方法学, 并能够达到大规模、 高通量及覆盖全基因组的目的。 However, the shRNA library is not a knockout library and can only partially silence gene expression. There are many deficiencies, such as the influence of specific gene expression often does not lead to phenotypic changes; may incorrectly inhibit irrelevant gene expression and the like. Although some knockout libraries have been reported, particularly KBM7 cells, which are part of haploid cells, can be used to construct knockout libraries, but their stability and efficiency are problematic, and the system is limited to specific cell lines, The scope of application is limited. Summary of the invention The present invention aims to construct a eukaryotic gene knockout library, and a method for efficiently and rapidly identifying gene functions based on functional screening, and can achieve large-scale, high-throughput and coverage of whole genomes.
为了实现本发明目的,本发明首先提供一种利用 CRISPR/CaS9系统构建真核 基因敲除文库的方法, 包括以下步骤: In order to achieve the object of the present invention, the present invention first provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Ca S 9 system, comprising the steps of:
1 )构建稳定表达 OCT1蛋白和 Cas9蛋白的真核细胞系: 将编码蛋白 OCT1和 Cas9的 DNA序列 通过柔性 Linker连接 , 然后 克隆至慢病毒载体 pOCTl-2A-Cas9-IRES-BSD ( SEQ ID No. l , 图 8 ) 上; 用构建好的载体转染真核 宿主细胞; 筛选稳定表达 OCT 1蛋白和 Cas9蛋白的真核细胞系; 1) Construction of a eukaryotic cell line stably expressing OCT1 protein and Cas9 protein: The DNA sequences encoding the proteins OCT1 and Cas9 were ligated via a flexible Linker, and then cloned into the lentiviral vector pOCTl-2A-Cas9-IRES-BSD (SEQ ID No.). l, Figure 8); transfecting eukaryotic host cells with the constructed vector; screening for eukaryotic cell lines stably expressing OCT 1 protein and Cas9 protein;
2 ) sgRNA质粒文库的构建: 2) Construction of sgRNA plasmid library:
i. 根据 sgRNA作用位点的 DNA序列 5' -G-Nx-NGG-3' , 其中 19 < x < 22, 设 计并合成针对上述作用位点的 sgRNA单体,针对同一个 sgRNA作用位点设计两个 sgRNA单体,其序列分别为正向单体: 5' -ACCG-Nx-3' ,反向单体: 5' -AAAC-N' χ-3' , 其中 N' X为 Nx的反向互补序列, N和 N' 表示碱基 、 T、 G或 C; i. According to the DNA sequence of sgRNA action site 5'-G-Nx-NGG-3', where 19 < x < 22, design and synthesize sgRNA monomer targeting the above-mentioned site of action, designing for the same sgRNA action site Two sgRNA monomers, the sequence of which is forward monomer: 5'-ACCG-Nx-3', reverse monomer: 5'-AAAC-N' χ-3', where N' X is the inverse of Nx To a complementary sequence, N and N' represent a base, T, G or C;
ii. 将上述合成的针对同一个 sgRNA作用位点的两个 sgRNA单体退火形成 具有粘性末端的双链 DNA, 并将针对所有基因合成的 sgRNA单体经退火形成的 双链 DNA等量混合; Ii. annealing the two sgRNA monomers synthesized above for the same sgRNA action site to form double-stranded DNA having sticky ends, and mixing the double-stranded DNA formed by annealing the sgRNA monomers synthesized for all genes in equal amounts;
iii. 将人 U6启动子连接 ccdB序列以及序列 5' -G-Nx-NGG-3'之后,连入 PLL3.7 载体中替换原载体上的 U6启动子, 将构建好的载体与 ii中得到的混合物混合, 加入 fismfil限制性内切酶和 T4连接酶, 37°C 5 min, 16 C 5 min, 重复 10个循环; Iii. After the human U6 promoter is ligated to the ccdB sequence and the sequence 5'-G-Nx-NGG-3', the PLL3.7 vector is ligated to replace the U6 promoter on the original vector, and the constructed vector and ii are obtained. Mix the mixture, add fisfil restriction endonuclease and T4 ligase, 37 ° C for 5 min, 16 C 5 min, repeat 10 cycles;
iv. 将上述产物转化至 Transl-Tl感受态细胞中, 提取质粒, 即构建得到 sgRNA质粒文库; Iv. transforming the above product into Transl-Tl competent cells, extracting the plasmid, and constructing the sgRNA plasmid library;
3 )将上述质粒与质粒 psPAX2和 PMD2.G共转染至 HEK293T细胞中, 培养细 胞, 收获病毒液; 3) co-transfecting the above plasmid with the plasmids psPAX2 and PMD2.G into HEK293T cells, culturing the cells, and harvesting the virus solution;
4 )用收获的病毒液按 0.01≤MOI≤ 0.3接种步骤 1 )中构建得到的真核细胞系, 细 胞经培养后, 使用流式细胞仪分选带有绿色荧光的细胞, 即获得真核基因敲除的细胞 文库。 4) Inoculate the eukaryotic cell line constructed in step 1) with the harvested virus solution at 0.01 ≤ MOI ≤ 0.3. After the cells are cultured, the cells with green fluorescence are sorted by flow cytometry to obtain the eukaryotic gene. Knockout cell library.
前述的方法,步骤 1 )中所述真核宿主细胞包括但不限于 HEK293T、HT1080、 HeLa细胞等。 The aforementioned method, the eukaryotic host cell in the step 1) includes, but is not limited to, HEK293T, HT1080, HeLa cells and the like.
前 述 的 方 法 , 步 骤 1 ) 中 所 述 柔 性 Linker序 列 为 p2A : In the method described above, the flexible Linker sequence described in step 1) is p2A:
GAGGAGAACCCTGGACCT-3 '。 本发明还提供由上述方法构建的真核基因敲除细胞文库。 GAGGAGAACCCTGGACCT-3 '. The present invention also provides a library of eukaryotic gene knockout cells constructed by the above method.
本发明进一步提供一种研究基因功能的方法, 基于所述真核基因敲除细胞 文库, 提取细胞的基因组 DNA, 设计引物, PCR扩增含有 sgRNA序列的 DNA片 段,利用深度测序技术(Deep Sequencing )对扩增产物进行测序,分析测序结果, 通过比较 sgRNA的富集程度, 来确定 sgRNA所对应基因的功能。 The present invention further provides a method for studying gene function, extracting genomic DNA of a cell based on the eukaryotic gene knockout cell library, designing a primer, PCR-amplifying a DNA fragment containing the sgRNA sequence, and using deep sequencing technology (Deep Sequencing) The amplified product was sequenced, the sequencing result was analyzed, and the function of the gene corresponding to the sgRNA was determined by comparing the degree of enrichment of the sgRNA.
其中,引物序列为正向引物: 5' -TATCTTGTGGAAAGGACGAAAC ACC-3 ' , 反向引物: 5' -AATACGGTTATCCACGCGGC-3'。 扩增的循环数为 25-30个。 Among them, the primer sequence is a forward primer: 5'-TATCTTGTGGAAAGGACGAAAC ACC-3 ', reverse primer: 5'-AATACGGTTATCCACGCGGC-3'. The number of cycles of amplification is 25-30.
本发明提供的真核基因敲除文库的构建方法, 先将编码 Cas9和 OCT1蛋白的基 因表达于真核细胞系中, 筛选获得稳定表达 Cas9的细胞系, 再进行文库构建和功能 筛选。 其最大的优点在于: 可将此方法应用于绝大多数真核细胞系中, 不受特定细 胞系的限制。 另外, 进行功能性筛选阳性率高, 背景值低。 大规模的筛选方法极大 降低了成本, 克服了单个制备基因敲除细胞, 所导致的时间和劳动成本高的问题。 附图说明 The method for constructing the eukaryotic gene knockout library provided by the present invention firstly expresses the gene encoding the Cas9 and OCT1 proteins in a eukaryotic cell line, selects a cell line stably expressing Cas9, and performs library construction and function screening. Its greatest advantage is that this method can be applied to most eukaryotic cell lines, independent of specific cell lines. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor costs caused by single preparation of knockout cells. DRAWINGS
图 1为本发明 Cas9表达载体(a )和 sgRNA表达载体(b ) 的结构示意图。 图 2为本发明利用 CRISPR/Cas系统构建真核基因敲除文库, 并用于基因功 能筛选的高通量方法学的实施流程图。 Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention. Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
图 3为本发明方法所涉及的系统在 HEK293T、 HT1080、 HeLa三个细胞系 中均可有效的造成基因组修复错误以达到基因敲除目的。 Fig. 3 shows that the system involved in the method of the present invention can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
图 4为应用本发明所述方法分别使用炭疽毒素嵌合毒素和白喉毒素进行筛选后的候 选阳性基因排序结果; 其中, a: 热图显示侧 sgRNA 结合深度测序分析筛 疽 毒素及白喉毒素宿主相关基因的结果汇总; b和 c: 分别为炭疽毒素和白喉毒素筛选后所 富集的 sgRNAs以及它们所针对的基因。 sgRNA的富集程度是通过计算标准化的平均实 验读值除以对照值得到。 图表数值表示三个值的平均值, 按照从高到低排列。 红色标记 表示 sgRNAs以及已知的毒素相关宿主基因。 d和 e: T7E1酶切法表示针对 AN XRl(d) 或 HBEGF(e)的各种不同 sgRNAs所造成的特定 DNA序列的插入或缺失突变率( indels )。 Figure 4 is a ranking of candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention; wherein: a: heat map shows side sgRNA binding deep sequencing analysis of sputum toxin and diphtheria toxin host Summary of gene results; b and c: sgRNAs enriched after anthrax toxin and diphtheria toxin screening, and the genes they target. The degree of enrichment of sgRNA is obtained by dividing the normalized average experimental reading by the control value. The chart values represent the average of the three values, arranged from high to low. Red markers indicate sgRNAs as well as known toxin-associated host genes. d and e: The T7E1 digestion method indicates the insertion or deletion mutation rate (indels) of a specific DNA sequence caused by various sgRNAs of AN XR1(d) or HBEGF(e).
图 5为本发明实施例 1 中炭疽毒素嵌合毒素筛选后被最大富集的 ANTXR1 基因对于炭疽毒素嵌合毒素具有较强抗性, 对白喉毒素不具有抗性。 Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention is highly resistant to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
图 6为本发明实施例 1中炭疽毒素嵌合毒素筛选后候选基因中 PECR基因对 于炭疽毒素嵌合毒素具有一定的抗性, 对白喉毒素不具有抗性。 Fig. 6 shows that the PECR gene of the anthrax toxin chimeric toxin in the first embodiment of the present invention has a certain resistance to the anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
图 7为本发明实施例 2中白喉毒素筛选后被最大富集的 HBEGF基因对于白 喉毒素具有较强抗性, 对炭疽毒素嵌合毒素不具有抗性。 图 8为本发明中载体 pOCTl-2A-Cas9-IRES-BSD的结构示意图。 具体实施方式 Figure 7 is a graph showing that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin. Figure 8 is a schematic view showing the structure of the vector pOCTl-2A-Cas9-IRES-BSD in the present invention. detailed description
以下实施例用于说明本发明, 但不用来限制本发明的范围。 若未特别指明, 实施 例均按照常规实验条件, 如 Sambrook等分子克隆实验手册( Sambrook J & Russell DW, Molecular cloning: a laboratory manual, 2001 ), 或按照制造厂商说明书建议的条件。 实施例 1 构建 CRISPER/Cas9基因敲除文库并筛选与炭疽毒素(anthrax toxin ) 细胞毒性相关的基因 The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. Unless otherwise specified, the examples are based on routine experimental conditions, such as the Sambrook J & Russell DW, Molecular cloning: a laboratory manual, 2001, or as suggested by the manufacturer's instructions. Example 1 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with anthrax toxin cytotoxicity
1. 文库 sgRNA的设计 1. Library Design of sgRNA
针对 296个基因, 每个基因找到 2-3个 sgRNA靶位点, 详见表 1。 For 296 genes, 2-3 sgRNA target sites were found for each gene, as shown in Table 1.
表 1 sgRNA文库的基因组成、 sgRNA靶位区域及用于构建 sgRNA质粒的引物序列 Table 1 Gene composition of sgRNA library, sgRNA target region and primer sequences for constructing sgRNA plasmid
/:/:/ O 98s8/-0H0si>l£ 6S0SSSZAV /:/:/ O 98s8/-0H0si>l£ 6S0SSSZAV
9 9
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV L 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV L
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
ν αιαιιαι νθΓΐ ν αιαιιαι νθΓΐ
。。 。 。 。 。 . . . . . .
98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 6 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 6
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV οτ S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Οτ
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV ττ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Ττ
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 飞 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV fly
飞 fly
飞 fly
飞 fly
工:) 飞 Worker :) fly
飞 fly
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 9T 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 9T
98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV LI 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV LI
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 81 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 81
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV oz 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Oz
98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV 98S8L0/PWZSlD/lDd 6Z600l/ST0Z OAV
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV zz 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Zz
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV ίΖ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Ζ
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 91 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 91
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV LZ 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV LZ
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 21 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV twenty one
S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61 S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 61
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV οε 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV Εε
98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV 98S8.0/M0ZN3/X3d 6Z600l/ST0Z OAV
2. 高表达 Cas9的 HeLa细胞的筛选 2. Screening of HeLa cells with high expression of Cas9
( 1 ) 将 OCT1和 Cas9的 DNA序列通过 2A连接并通过 Gibson克隆方法装载到 慢病毒载体 pLenti-CMV-MCSSV-Bsd上; (1) The DNA sequences of OCT1 and Cas9 were ligated through 2A and loaded into the lentiviral vector pLenti-CMV-MCSSV-Bsd by Gibson cloning method;
(2)将上述载体通过包装慢病毒感染的方法转入目标细胞; (2) transferring the above vector into a target cell by a method of packaging a lentivirus infection;
(3 )在上述细胞的培养液中加入杀稻瘟菌素 (blasticidin)进行筛选, 并挑 取稳定表达 Cas9的单克隆; (3) adding blasticidin to the culture medium of the above cells for screening, and picking up a single clone stably expressing Cas9;
3. 文库质粒的构建 3. Construction of library plasmid
(4) 寻找 sgRNA作用位点, 序列为 5' -G-Nx-NGG-3' , 其中 19<x<22; (4) Find the sgRNA action site, the sequence is 5'-G-Nx-NGG-3', where 19<x<22;
( 5 )合成针对上述作用位点的 sgRNA单体, 针对每一个位点, 其序列为, 正向: 5' -ACCG-Nx-3' , 反向: 5' -AAAC-N' χ-3' , 其中 N' x为 Nx的反向互 补配对序列; (5) synthesizing sgRNA monomers targeting the above-mentioned action sites, for each site, the sequence is, forward: 5'-ACCG-Nx-3', reverse: 5'-AAAC-N' χ-3 ' , where N' x is the reverse complementary pairing sequence of Nx;
(6) sgRNA载体的构建, 将人的 U6启动子连接 ccdB以及 gRNA结构, 用酶 Xba 1和 X/w 1连入 PLL3.7载体中替换原载体上的 U6启动子; (6) Construction of sgRNA vector, human U6 promoter is ligated to ccdB and gRNA structure, and enzymes Xba 1 and X/w 1 are ligated into PLL3.7 vector to replace U6 promoter on original vector;
(7)将上述合成的针对同一个 sgRNA位点的两个单体, 用 TE缓冲液稀释到 ΙΟ μΜ,各取 22.5μ1,加入 5μ1 Taq Hifi Buffer,加热至 95 °C ,然后自然冷却至室温;(7) Diluting the two monomers synthesized above for the same sgRNA site with TE buffer to ΙΟ μΜ, each take 22.5μ1, add 5μ1 Taq Hifi Buffer, heat to 95 °C, then naturally cool to room temperature;
( 8 ) 上述针对所有基因 sgRNA的产物等量混合; (8) The above-mentioned products for all gene sgRNAs are mixed in equal amounts;
( 9 )上述混合物与 (6 ) 中构建的载体混合, 加入 mSI限制性内切酶和 T4 连接酶, 37°C 5 min, 16°C 5 min, 重复 10个循环; (9) The above mixture is mixed with the vector constructed in (6), and mSI restriction enzyme and T4 ligase are added, and the mixture is repeated at 37 ° C for 5 min, 16 ° C for 5 min, and repeated for 10 cycles;
( 10 ) 上述产物转化至 Transl-Tl感受态细胞中; (10) the above product is transformed into Transl-Tl competent cells;
( 11 )从上述转化产物中提取质粒, 构建文库质粒; (11) extracting a plasmid from the above transformation product to construct a library plasmid;
4. 文库病毒的包装 4. Packaging of library viruses
将 293T细胞以 3 X 106的密度平铺于 4个 10cm直径的细胞培养板中, 使用聚氮 丙啶 (PEI )将文库质粒和其它两种病毒包装质粒 psPAX2和 PMD2.G转入细胞, 70小时后, 收获病毒液; 293T cells were plated at a density of 3×10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
5. 文库细胞的构建 5. Construction of library cells
将筛选出的表达 Cas9的 HeLa细胞以 4 χ 106的密度平铺于 10个 15cm直径的细 胞培养板中, 用上述病毒液按 MOI = 0.05进行感染, 感染 48小时后, 使用流式细 胞仪筛选出表达绿色荧光的细胞; The selected Cas9-expressing HeLa cells were plated at a density of 4 χ 10 6 in 10 15 cm-diameter cell culture plates, infected with the above virus solution at MOI = 0.05, and 48 hours after infection, using a flow cytometer. Screening for cells expressing green fluorescence;
6. 使用炭疽毒素进行筛选 6. Screening with anthrax toxin
将筛选出的细胞以 1 X 106的密度平铺于 10个 10cm的细胞培养板,共三组平行 实验, 在培养液中加入 PA蛋白 70 ng/mL, LFn-DTA蛋白 50 ng/mL, 培养 48小时, 更换新鲜培养液, 重复此过程三次; The selected cells were plated at a density of 1×10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. The PA protein was 70 ng/mL and the LFn-DTA protein was 50 ng/mL. After culturing for 48 hours, replace the fresh medium and repeat the process three times;
7. 提取基因组 DNA并扩增 7. Extract genomic DNA and amplify
提取存活的细胞和另外三组未作任何处理的文库细胞的基因组 DN A , 使用 上述引物进行 PCR扩增, 每组作为模板的基因组 DNA总量为 8 μ§, PCR进行 26个 循环, 纯化 PCR产物; The genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification. The total amount of genomic DNA of each group as a template was 8 μ § , PCR was performed for 26 cycles, and PCR was performed. product;
8. 测序并分析 8. Sequencing and analysis
纯化后的 PCR产物使用 HiSeq2500进行测序, 并根据 sgRNA在毒素处理前后 的丰度变化进行排序, 排在前三位的均为已知的炭疽毒素的受体。 并寻找到一个 新的可能与炭疽毒素毒性作用有关的基因 PECR。 The purified PCR products were sequenced using HiSeq2500 and ranked according to the abundance changes of sgRNA before and after toxin treatment, and the top three were all known receptors for anthrax toxin. And to find a new gene PECR that may be related to the toxicity of anthrax toxin.
实施例 2 构建 CRISPER/Cas9基因敲除文库并筛选与白喉毒素 (diphtheria toxin )细胞毒性相关的基因 Example 2 Construction of a CRISPR/Cas9 knockout library and screening for genes associated with diphtheria toxin cytotoxicity
1. 文库 sgRNA的设计 1. Library Design of sgRNA
针对 296个基因, 每个基因找到 2-3个 sgRNA靶位点, 详见表 1。 For 296 genes, 2-3 sgRNA target sites were found for each gene, as shown in Table 1.
2. 高表达 Cas9的 HeLa细胞的筛选 ( 1 ) 将 OCT1和 Cas9的 DNA序列通过 2A连接并通过 Gibson克隆方法装载到 慢病毒载体 pLenti-CMV-MCSSV-Bsd上; 2. Screening of HeLa cells with high expression of Cas9 (1) The DNA sequences of OCT1 and Cas9 were ligated by 2A and loaded into the lentiviral vector pLenti-CMV-MCSSV-Bsd by Gibson cloning method;
(2)将上述载体通过包装慢病毒感染的方法转入目标细胞; (2) transferring the above vector into a target cell by a method of packaging a lentivirus infection;
(3 )在上述细胞的培养液中加入杀稻瘟菌素 ( blasticidin )进行筛选, 并挑 取稳定表达 Cas9的单克隆; (3) adding blasticidin to the culture medium of the above cells for screening, and picking up a single clone stably expressing Cas9;
3. 文库质粒的构建 3. Construction of library plasmid
(4) 寻找 sgRNA作用位点, 序列为 5' -G-Nx-NGG-3' , 其中 19<x<22; (4) Find the sgRNA action site, the sequence is 5'-G-Nx-NGG-3', where 19<x<22;
( 5 )合成针对上述作用位点的 sgRNA单体, 针对每一个位点, 其序列为, 正向: 5' -ACCG-Nx-3' , 反向: 5' -AAAC-N' χ-3' , 其中 N' x为 Nx的反向互 补配对序列; (5) synthesizing sgRNA monomers targeting the above-mentioned action sites, for each site, the sequence is, forward: 5'-ACCG-Nx-3', reverse: 5'-AAAC-N' χ-3 ' , where N' x is the reverse complementary pairing sequence of Nx;
(6) sgRNA载体的构建, 将人的 U6启动子连接 ccdB以及 gRNA结构, 用酶 Xba 1和 X/w 1连入 PLL3.7载体中替换原载体上的 U6启动子; (6) Construction of sgRNA vector, human U6 promoter is ligated to ccdB and gRNA structure, and enzymes Xba 1 and X/w 1 are ligated into PLL3.7 vector to replace U6 promoter on original vector;
(7)将上述合成的针对同一个 sgRNA位点的两个单体, 用 TE缓冲液稀释到 ΙΟμΜ, 各取 22.5μ1, 加入 5μ1 Taq Hifi Buffer, 加热至 95°C, 然后自然冷却至室温; (7) The above two monomers synthesized for the same sgRNA site were diluted to ΙΟμΜ with TE buffer, each taken 22.5 μl, added with 5 μl Taq Hifi Buffer, heated to 95 ° C, and then naturally cooled to room temperature;
(8) 上述针对所有基因 sgRNA的产物等量混合; (8) The above-mentioned products for all gene sgRNA are mixed in equal amounts;
(9)上述混合物与 (6) 中构建的载体混合, 加入 mSI限制性内切酶和 T4 连接酶, 37°C 5 min, 16°C 5 min, 重复 10个循环; (9) The above mixture is mixed with the vector constructed in (6), and mSI restriction endonuclease and T4 ligase are added, and the mixture is repeated at 37 ° C for 5 min, 16 ° C for 5 min, and repeated for 10 cycles;
( 10) 上述产物转化至 Transl-Tl感受态细胞中; (10) the above product is transformed into Transl-Tl competent cells;
( 11 )从上述转化产物中提取质粒, 构建文库质粒; (11) extracting a plasmid from the above transformation product to construct a library plasmid;
4. 文库病毒的包装 4. Packaging of library viruses
将 293T细胞以 3 X 106的密度平铺于 4个 10cm直径的细胞培养板中, 使用聚氮 丙啶 (PEI)将文库质粒和其它两种病毒包装质粒 psPAX2和 PMD2.G转入细胞, 70小时后, 收获病毒液; 293T cells were plated at a density of 3×10 6 in four 10 cm diameter cell culture plates, and the library plasmid and the other two viral packaging plasmids psPAX2 and PMD2.G were transferred into the cells using polyethylenimine (PEI). After 70 hours, the virus solution was harvested;
5. 文库细胞的构建 5. Construction of library cells
将筛选出的表达 Cas9的 HeLa细胞以 4 χ 106的密度平铺于 10个 15cm直径的细 胞培养板中, 用上述病毒液按 MOI = 0.05进行感染, 感染 48小时后, 使用流式细 胞仪筛选出表达绿色荧光的细胞; The selected Cas9-expressing HeLa cells were plated at a density of 4 χ 10 6 in 10 15 cm-diameter cell culture plates, infected with the above virus solution at MOI = 0.05, and 48 hours after infection, using a flow cytometer. Screening for cells expressing green fluorescence;
6. 使用白喉毒素进行筛选 6. Screening with diphtheria toxin
将筛选出的细胞以 1 X 106的密度平铺于 10个 10cm的细胞培养板,共三组平行 实验, 在培养液中加入 DT蛋白 7.5 ng/mL, 培养 48小时, 更换新鲜培养液, 重复 此过程三次; 7. 提取基因组 DNA并扩增 The selected cells were plated at a density of 1×10 6 in 10 10 cm cell culture plates, and three groups of parallel experiments were performed. DT protein 7.5 ng/mL was added to the culture medium, cultured for 48 hours, and the fresh culture solution was replaced. Repeat this process three times; 7. Extract genomic DNA and amplify
提取存活的细胞和另外三组未作任何处理的文库细胞的基因组 DN A , 使用 上述引物进行 PCR扩增, 每组作为模板的基因组 DNA总量为 8 μ§, PCR进行 26个 循环, 纯化 PCR产物; The genomic DNA DN A of the surviving cells and the other three groups of untreated library cells were extracted, and the above primers were used for PCR amplification. The total amount of genomic DNA of each group as a template was 8 μ § , PCR was performed for 26 cycles, and PCR was performed. product;
8. 测序并分析 8. Sequencing and analysis
纯化后的 PCR产物使用 HiSeq2500进行测序, 并根据 sgRNA在毒素处理前后 的丰度变化进行排序, 排在第一位的为已知的白喉毒素的受体。 The purified PCR product was sequenced using HiSeq 2500 and sorted according to the abundance change of sgRNA before and after toxin treatment, and the first place was the known receptor for diphtheria toxin.
图 1为本发明 Cas9表达载体(a )和 sgRNA表达载体(b ) 结构示意图。 图 2为本发明利用 CRISPR/Cas系统构建真核基因敲除文库,并用于基因功 能筛选的高通量方法学的实施流程图。 Figure 1 is a schematic view showing the structure of the Cas9 expression vector (a) and the sgRNA expression vector (b) of the present invention. Figure 2 is a flow chart showing the implementation of a high-throughput method for constructing a eukaryotic gene knockout library using the CRISPR/Cas system and for gene function screening.
图 3为本编码方法所涉及的系统在 HEK293T、 HT1080、 HeLa三个细胞系 中均可有效的造成基因组修复错误以达到基因敲除目的。 Fig. 3 shows that the system involved in the coding method can effectively cause genomic repair errors in the three cell lines HEK293T, HT1080 and HeLa to achieve gene knockout.
图 4为应用本发明所述方法分别使用炭疽毒素嵌合毒素和白喉毒素进行筛 选后的候选阳性基因排序结果。 Fig. 4 is a result of sorting candidate positive genes after screening using anthrax toxin chimeric toxin and diphtheria toxin, respectively, using the method of the present invention.
图 5为本发明实施例 1中炭疽毒素嵌合毒素筛选后被最大富集的 ANTXR1 基因对于炭疽毒素嵌合毒素具有较强抗性, 对白喉毒素不具有抗性。 Fig. 5 is a graph showing that the ANTXR1 gene which is most enriched after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has strong resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
图 6为本发明实施例 1 中炭疽毒素嵌合毒素筛选后候选基因中 PECR基因 对于炭疽毒素嵌合毒素具有一定的抗性, 对白喉毒素不具有抗性。 Fig. 6 is a diagram showing that the PECR gene in the candidate gene after screening for anthrax toxin chimeric toxin in Example 1 of the present invention has certain resistance to anthrax toxin chimeric toxin and is not resistant to diphtheria toxin.
图 7为本发明实施例 2中白喉毒素筛选后被最大富集的 HBEGF基因对于白 喉毒素具有较强抗性, 对炭疽毒素嵌合毒素不具有抗性。 Fig. 7 shows that the HBEGF gene which is most enriched after screening for diphtheria toxin in Example 2 of the present invention is highly resistant to diphtheria toxin and is not resistant to anthrax toxin chimeric toxin.
虽然, 上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述, 但在本发明基础上, 可以对之作一些修改或改进,这对本领域技术人员而言是显 而易见的。 因此, 在不偏离本发明精神的基础上所做的这些修改或改进, 均属于 本发明要求保护的范围。 工业实用性 本发明提供的利用 CRISPR/Cas9系统构建真核基因敲除文库的方法, 该方 法的最大优点在于: 可将本方法应用于绝大多数真核细胞系中, 不受特定细胞系 的限制。 另外, 进行功能性筛选阳性率高, 背景值低。 大规模的筛选方法极大降 低了成本, 克服了单个制备基因敲除细胞, 所导致的时间和劳动成本高的问题。 参考文献 Although the present invention has been described in detail with reference to the preferred embodiments of the present invention, it will be apparent to those skilled in the art. Therefore, such modifications or improvements made without departing from the spirit of the invention are intended to be within the scope of the invention. INDUSTRIAL APPLICABILITY The present invention provides a method for constructing a eukaryotic gene knockout library using the CRISPR/Cas9 system, and the greatest advantage of the method is that the method can be applied to most eukaryotic cell lines without being affected by a specific cell line. limit. In addition, the functional screening has a high positive rate and a low background value. The large-scale screening method greatly reduces the cost and overcomes the problem of high time and labor cost caused by single preparation of knockout cells. references
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini,
L.A., et al. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science. L.A., et al. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science.
Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, IE., Norville, IE., and Church, G.M. Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, IE., Norville, IE., and Church, G.M.
(2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826.
Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, L, Beausejour, CM., Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, L, Beausejour, CM.,
Waite, A. J., Wang, N.S., Kim, K.A., et al. (2007). An improved zinc -finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785. Waite, A. J., Wang, N.S., Kim, K.A., et al. (2007). An improved zinc -finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785.
Miller, J.C., Tan, S., Qiao, G, Barlow, K.A., Wang, J., Xia, D.F Meng, X., Paschon, D.E Leung, E., Hinkley, S丄, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29, 143-148. Miller, JC, Tan, S., Qiao, G, Barlow, KA, Wang, J., Xia, DF Meng, X., Paschon, DE Leung, E., Hinkley, S丄, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29, 143-148.
Porteus, M.H., and Baltimore, D. (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763. Porteus, M.H., and Baltimore, D. (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763.
Wood, A.J., Lo, T.W., Zeitler, B., Pickle, C.S., Ralston, E.J., Lee, A.H Amora, R., Miller, J.C., Leung, E., Meng, X., et al (2011). Targeted genome editing across species using ZFNs and TALENs. Science 333, 307. Wood, AJ, Lo, TW, Zeitler, B., Pickle, CS, Ralston, EJ, Lee, AH Amora, R., Miller, JC, Leung, E., Meng, X., et al (2011). Targeted Particle editing across species using ZFNs and TALENs. Science 333, 307.
Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M., and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nature biotechnology 29, 149-153. Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, GM, and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. 149-153.
序列表 Sequence table
< 110> 北京大学 < 110> Peking University
< 120> 利用 CRISPR/Cas9系统构建真核基因敲除文库的方法 < 120> Method for constructing eukaryotic gene knockout library using CRISPR/Cas9 system
< 130> KHP143111702 < 130> KHP143111702
< 160> 4 < 160> 4
< 170> Patentln vers ion 3. 3 < 170> Patentln vers ion 3. 3
<210> 1 <210> 1
<211> 8217 <211> 8217
<212> DNA <212> DNA
<213> 载体 pOCTl- 2A- Cas9- IRES- BSD <213> Carrier pOCTl-2A- Cas9- IRES- BSD
<400> 1 <400> 1
cgataagctt gggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg 60 cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata 120 gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta 180 catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc 240 gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca gtacatctac 300 gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga 360 tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg 420 ttttggcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg 480 caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctcg tttagtgaac 540 cgtcagatcg cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgacta 600 ctagtttacc ggtgggggcc cccggcgcgc cggtgtacac cctgcagggg tttatgaaca 660 atccgtcaga aaccagtaaa ccatctatgg agagtggaga tggcaacaca ggcacacaaa 720 ccaatggtct ggactttcag aagcagcctg tgcctgtagg aggagcaatc tcaacagccc 780 aggcgcaggc tttccttgga catctccatc aggtccaact cgctggaaca agtttacagg 840 ctgctgctca gtctttaaat gtacagtcta aatctaatga agaatcgggg gattcgcagc 900 agccaagcca gccttcccag cagccttcag tgcaggcagc cattccccag acccagctta 960 tgctagctgg aggacagata actgggctta ctttgacgcc tgcccagcaa cagttactac 1020 tccagcaggc acaggcacag gcacagctgc tggctgctgc agtgcagcag cactccgcca 1080 gccagcagca cagtgctgct ggagccacca tctccgcctc tgctgccacg cccatgacgc 1140 agatccccct gtctcagccc atacagatcg cacaggatct tcaacaactg caacagcttc 1200 aacagcagaa tctcaacctg caacagtttg tgttggtgca tccaaccacc aatttgcagc 1260 cagcgcagtt tatcatctca cagacgcccc agggccagca gggtctcctg caagcgcaaa 1320 atcttctaac gcaactacct cagcaaagcc aagccaacct cctacagtcg cagccaagca 1380 tcaccctcac ctcccagcca gcaaccccaa cacgcacaat agcagcaacc ccaattcaga 1440 cacttccaca gagccagtca acaccaaagc gaattgatac tcccagcttg gaggagccca 1500 gtgaccttga ggagcttgag cagtttgcca agaccttcaa acaaagacga atcaaacttg 1560 gattcactca gggtgatgtt gggctcgcta tggggaaact atatggaaat gacttcagcc 1620 aaactaccat ctctcgattt gaagccttga acctcagctt taagaacatg tgcaagttga 1680 agccactttt agagaagtgg ctaaatgatg cagagaacct ctcatctgat tcgtccctct 1740 ccagcccaag tgccctgaat tctccaggaa ttgagggctt gagccgtagg aggaagaaac 1800 gcaccagcat agagaccaac atccgtgtgg ccttagagaa gagtttcttg gagaatcaaa 1860 agcctacctc ggaagagatc actatgattg ctgatcagct caatatggaa aaagaggtga 1920 ttcgtgtttg gttctgtaac cgccgccaga aagaaaaaag aat caaccca ccaagcagtg 1980 gtgggaccag cagctcacct attaaagcaa ttttccccag cccaacttca ctggtggcga 2040 ccacaccaag ccttgtgact agcagtgcag caactaccct cacagtcagc cctgtcctcc 2100 ctctgaccag tgctgctgtg acgaatcttt cagttacagg cacttcagac accacctcca 2160 acaacacagc aaccgtgatt tccacagcgc ctccagcttc ctcagcagtc acgtccccct 2220 ctctgagtcc ctccccttct gcctcagcct ccacctccga ggcatccagt gccagtgaga 2280 ccagcacaac acagaccacc tccactcctt tgtcctcccc tcttgggacc agccaggtga 2340 tggtgacagc atcaggtttg caaacagcag cagctgctgc ccttcaagga gctgcacagt 2400 tgccagcaaa tgccagtctt gctgccatgg cagctgctgc aggactaaac ccaagcctga 2460 tggcaccctc acagtttgcg gctggaggtg ccttactcag tctgaatcca gggaccctga 2520 gcggtgctct cagcccagct ctaatgagca acagtacact ggcaactatt caagctcttg 2580 cttctggtgg ctctcttcca at aacat cac ttgatgcaac tgggaacctg gtatttgcca 2640 atgcgggagg agcccccaac atcgtgactg cccctctgtt cctgaaccct cagaacctct 2700 ctctgctcac cagcaaccct gttagcttgg tctctgccgc cgcagcatct gcagggaact 2760 ctgcacctgt agccagcctt cacgccacct ccacctctgc tgagtccatc cagaactctc 2820 tcttcacagt ggcctctgcc agcggggctg cgtccaccac caccaccgcc tccaaggcac 2880 agggaagcgg agctactaac ttcagcctgc tgaagcaggc tggagacgtg gaggagaacc 2940 ctggacctat ggccccaaag aagaagcgga aggtcggtat ccacggtgtc ccagcagcca 3000 tggacaagaa gtactccatt gggctcgata tcggcacaaa cagcgtcggc tgggccgtca 3060 ttacggacga gtacaaggtg ccgagcaaaa aattcaaagt tctgggcaat accgatcgcc 3120 acagcataaa gaagaacctc attggcgccc tcctgttcga ctccggggag acggccgaag 3180 ccacgcggct caaaagaaca gcacggcgca gatatacccg cagaaagaat cggatctgct 3240 acctgcagga gatctttagt aatgagatgg ctaaggtgga tgactctttc ttccataggc 3300 tggaggagtc ctttttggtg gaggaggata aaaagcacga gcgccaccca atctttggca 3360 atatcgtgga cgaggtggcg taccatgaaa agtacccaac catatatcat ctgaggaaga 3420 agcttgtaga cagtactgat aaggctgact tgcggttgat ctatctcgcg ctggcgcata 3480 tgatcaaatt tcggggacac ttcctcatcg agggggacct gaacccagac aacagcgatg 3540 tcgacaaact ctttatccaa ctggttcaga cttacaatca gcttttcgaa gagaacccga 3600 tcaacgcatc cggagttgac gccaaagcaa tcctgagcgc taggctgtcc aaatcccggc 3660 ggctcgaaaa cctcatcgca cagctccctg gggagaagaa gaacggcctg tttggtaatc 3720 ttatcgccct gtcactcggg ctgaccccca actttaaatc taacttcgac ctggccgaag 3780 atgccaagct tcaactgagc aaagacacct acgatgatga tctcgacaat ctgctggccc 3840 agatcggcga ccagtacgca gacctttttt tggcggcaaa gaacctgtca gacgccattc 3900 tgctgagtga tattctgcga gtgaacacgg agatcaccaa agctccgctg agcgctagta 3960 tgatcaagcg ctatgatgag caccaccaag acttgacttt gctgaaggcc cttgtcagac 4020 agcaactgcc tgagaagtac aaggaaattt tcttcgatca gtctaaaaat ggctacgccg 4080 gatacattga cggcggagca agccaggagg aat 111 acaa atttattaag cccatcttgg 4140 aaaaaatgga cggcaccgag gagctgctgg taaagcttaa cagagaagat ctgttgcgca 4200 aacagcgcac tttcgacaat ggaagcatcc cccaccagat tcacctgggc gaactgcacg 4260 ctatactcag gcggcaagag gatttctacc cctttttgaa agataacagg gaaaagattg 4320 agaaaatcct cacatttcgg ataccctact atgtaggccc cctcgcccgg ggaaattcca 4380 gattcgcgtg gatgactcgc aaatcagaag agaccatcac tccctggaac ttcgaggaag 4440 tcgtggataa gggggcctct gcccagtcct tcatcgaaag gatgactaac tttgataaaa 4500 atctgcctaa cgaaaaggtg cttcctaaac actctctgct gtacgagtac ttcacagttt 4560 gg gggggg aaaaaaaatt teccccctctcc ctcccccccc cctaactta ctccaa 7200 cgataagctt gggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg 60 cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata 120 gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta 180 catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg 240 gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca gtacatctac 300 gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga 360 tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg 420 ttttggcacc taaatggccc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg 480 caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctcg tttagtgaac 540 cgtcagatcg cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgacta 600 ctagtttacc ggtgggggcc cccggcgcgc cggtgtacac cctgcagggg tttatgaaca 660 atccgtcaga aaccagtaaa ccatctatgg agagtggaga tggcaacaca ggcacacaaa 720 ccaatggtct ggactttcag aagcagcctg tgcctgtagg aggagcaatc tcaacagccc 780 aggcgcaggc tttccttgga catctccatc aggtccaact cgctggaaca agtttacagg 840 ctgctgctca gtctttaaat gtacagtcta aatctaatga agaatcgggg gattcgcagc 900 agccaagcca gccttcccag cagccttcag tgcaggcagc cattccccag acccagctta 960 tgctagctgg aggacagata actgggctta ctttgacgcc tgcccagcaa cagttactac 1020 tccagcaggc acaggcacag gcacagctgc tggctgctgc agtgcagcag cactccgcca 1080 gccagcagca cagtgctgct ggagccacca tctccgcctc tgctgccacg cccatgacgc 1140 agatccccct gtctcagccc atacagatcg cacaggatct tcaacaactg caacagcttc 1200 aacagcagaa tctcaacctg caacagtttg tgttggtgca tccaaccacc aatttgcagc 1260 cagcgcagtt tatcatctca cagacgcccc agggccagca gggtctcctg caagcgcaaa 1320 atcttctaac gcaactacct cagcaaagcc aagccaacct cctacagtcg cagccaagca 1380 tcaccctcac ctcccagcca gcaaccccaa cacgcacaat agcagcaacc ccaattcaga 1440 cacttccaca gagccagtca acaccaaagc gaattgatac tcccagcttg gaggagccca 1500 gtgaccttga ggagcttgag cagtttgcca agaccttcaa acaaagacga atcaaacttg 1560 gattcactca gggtgatgtt gggctcgcta tggggaaact atatggaaat gacttcagcc 1620 aaactaccat ctctcgattt gaagccttga acctcagctt taagaacatg tgcaagttga 1680 agccactttt agagaagtgg ctaaatg Atg cagagaacct ctcatctgat tcgtccctct 1740 ccagcccaag tgccctgaat tctccaggaa ttgagggctt gagccgtagg aggaagaaac 1800 gcaccagcat agagaccaac atccgtgtgg ccttagagaa gagtttcttg gagaatcaaa 1860 agcctacctc ggaagagatc actatgattg ctgatcagct caatatggaa aaagaggtga 1920 ttcgtgtttg gttctgtaac cgccgccaga aagaaaaaag aat caaccca ccaagcagtg 1980 gtgggaccag cagctcacct attaaagcaa ttttccccag cccaacttca ctggtggcga 2040 ccacaccaag ccttgtgact agcagtgcag caactaccct cacagtcagc cctgtcctcc 2100 ctctgaccag tgctgctgtg acgaatcttt cagttacagg cacttcagac accacctcca 2160 acaacacagc aaccgtgatt tccacagcgc ctccagcttc ctcagcagtc acgtccccct 2220 ctctgagtcc ctccccttct gcctcagcct ccacctccga ggcatccagt gccagtgaga 2280 ccagcacaac acagaccacc tccactcctt tgtcctcccc tcttgggacc agccaggtga 2340 tggtgacagc atcaggtttg caaacagcag cagctgctgc ccttcaagga gctgcacagt 2400 tgccagcaaa tgccagtctt gctgccatgg cagctgctgc aggactaaac ccaagcctga 2460 tggcaccctc acagtttgcg gctggaggtg ccttactcag tctgaatcca gggaccctga 2520 gcggtgctct cagcccagct ctaatgagca acagtacact ggcaactatt caagctcttg 2580 cttctggtgg ctctcttcca at aacat cac ttgatgcaac tgggaacctg gtatttgcca 2640 atgcgggagg agcccccaac atcgtgactg cccctctgtt cctgaaccct cagaacctct 2700 ctctgctcac cagcaaccct gttagcttgg tctctgccgc cgcagcatct gcagggaact 2760 ctg cacctgt agccagcctt cacgccacct ccacctctgc tgagtccatc cagaactctc 2820 tcttcacagt ggcctctgcc agcggggctg cgtccaccac caccaccgcc tccaaggcac 2880 agggaagcgg agctactaac ttcagcctgc tgaagcaggc tggagacgtg gaggagaacc 2940 ctggacctat ggccccaaag aagaagcgga aggtcggtat ccacggtgtc ccagcagcca 3000 tggacaagaa gtactccatt gggctcgata tcggcacaaa cagcgtcggc tgggccgtca 3060 ttacggacga gtacaaggtg ccgagcaaaa aattcaaagt tctgggcaat accgatcgcc 3120 acagcataaa gaagaacctc attggcgccc tcctgttcga ctccggggag acggccgaag 3180 ccacgcggct caaaagaaca gcacggcgca gatatacccg cagaaagaat cggatctgct 3240 acctgcagga gatctttagt aatgagatgg ctaaggtgga tgactctttc ttccataggc 3300 tggaggagtc ctttttggtg gaggaggata aaaagcacga gcgccaccca atctttggca 3360 atatcgtgga cgaggtggcg taccatgaaa agtacccaac catatatcat ctgaggaaga 3420 agcttgtaga cagtactgat aaggctgact tgcggttgat ctatctcgcg ctggcgcata 3480 tgatcaaatt tcggggacac ttcctcatcg agggggacct gaacccagac aacagcgatg 3540 tcgacaaact ctttatccaa ctggttcaga cttacaatca gcttttcgaa gagaacccga 3600 tcaacgcat c cggagttgac gccaaagcaa tcctgagcgc taggctgtcc aaatcccggc 3660 ggctcgaaaa cctcatcgca cagctccctg gggagaagaa gaacggcctg tttggtaatc 3720 ttatcgccct gtcactcggg ctgaccccca actttaaatc taacttcgac ctggccgaag 3780 atgccaagct tcaactgagc aaagacacct acgatgatga tctcgacaat ctgctggccc 3840 agatcggcga ccagtacgca gacctttttt tggcggcaaa gaacctgtca gacgccattc 3900 tgctgagtga tattctgcga gtgaacacgg agatcaccaa agctccgctg agcgctagta 3960 tgatcaagcg ctatgatgag caccaccaag acttgacttt gctgaaggcc cttgtcagac 4020 agcaactgcc tgagaagtac aaggaaattt tcttcgatca gtctaaaaat ggctacgccg 4080 gatacattga cggcggagca agccaggagg aat 111 acaa atttattaag cccatcttgg 4140 aaaaaatgga cggcaccgag gagctgctgg taaagcttaa cagagaagat ctgttgcgca 4200 aacagcgcac tttcgacaat ggaagcatcc cccaccagat tcacctgggc gaactgcacg 4260 ctatactcag gcggcaagag gatttctacc cctttttgaa agataacagg gaaaagattg 4320 agaaaatcct cacatttcgg ataccctact atgtaggccc cctcgcccgg ggaaattcca 4380 gattcgcgtg gatgactcgc aaatcagaag agaccatcac tccctggaac ttcgaggaag 4440 Tcgtggataa gg Gggcctct gcccagtcct tcatcgaaag gatgactaac tttgataaaa 4500 atctgcctaa cgaaaaggtg cttcctaaac actctctgct gtacgagtac ttcacagttt 4560 Gg gggggg aaaaaaaatt teccccctctcc ctcccccccc cctaactta ctccaa 7200
ggggg ggggggg ggg acctctctcactctaacaactc ctctctac taaaaacttcaacta 7140 Ggggg ggggggg ggg acctctctcactctaacaactc ctctctac taaaaacttcaacta 7140
gggggggggg gggg atccta cccacact attcatcat caattacctctataa acaaaatc 7080 Gggggggggg gggg atccta cccacact attcatcat caattacctctataa acaaaatc 7080
ggg ggg ggggg ctcacctt caatacttcacaccacca taacaaaactacacc tctacaaa 7020 Ggg ggg ggggg ctcacctt caatacttcacaccacca taacaaaactacacc tctacaaa 7020
ggg ggggggggggg ccatcaacacaaa aacattatcc actttttac tctaccaac ttccc 6960 Ggg ggggggggggg ccatcaacacaaa aacattatcc actttttac tctaccaac ttccc 6960
ggg gggggggggg tcctccca cctaacctcataatc tttctctta caataacac aataac 6900 Ggg gggggggggg tcctccca cctaacctcataatc tttctctta caataacac aataac 6900
g ggggggggg ctaccttataatcatc acaaataa caattctcc aaaaata 6840 g ggggggggg ctaccttataatcatc acaaataa caattctcc aaaaata 6840
g gggggggg ggggggg actataaaactcaaa tctcccaa ataatacaaacact ttctaac 6780 g gggggggg ggggggg actataaaactcaaa tctcccaa ataatacaaacact ttctaac 6780
ggggggggggggg aaaataa cactca ctccctcta aatacttaa tttctttat ctccacc 6720 Ggggggggggggg aaaataa cactca ctccctcta aatacttaa tttctttat ctccacc 6720
ggggggggggggg ggggg actctctctt tacttaa aaccca aacaatct cctatccactc 6660 Ggggggggggggg ggggg actctctctt tacttaa aaccca aacaatct cctatccactc 6660
ggg ggggggggg ttctcacaaaatat aaaatca aaaaaacct catcattaa cttcccaat 6600 Ggg ggggggggg ttctcacaaaatat aaaatca aaaaaacct catcattaa cttcccaat 6600
ggg gggggg gggg aaactctcatcaca atcatacatcaactt caaaaaaac cccatcact 6540 Ggg gggggg gggg aaactctcatcaca atcatacatcaactt caaaaaaac cccatcact 6540
gg ggggggggggggggg acattacttttcc aaataa aaaatc aaaactca 6480 Gg ggggggggggggggg acattacttttcc aaataa aaaatc aaaactca 6480
ggggggggggggg caccaaaaa aattac cccaaaaat accatt cattctcct acatcctt 6420 Ggggggggggggg caccaaaaa aattac cccaaaaat accatt cattctcct acatcctt 6420
gggggg gggg gggggg aacca cttctccaaaaatatcc tcccaaaaaacacac aactatc 6360 Gggggg gggg gggggg aacca cttctccaaaaatatcc tcccaaaaaacacac aactatc 6360
ggg ggggggggggggg cacatccaatcct tccatccc ataacat cttaaaaa accaatac 6300 Ggg ggggggggggggg cacatccaatcct tccatccc ataacat cttaaaaa accaatac 6300
ggg ggggggg ggggggggg cacttatca aacaaacaaaacaa aaatcttacaat aatttc 6240 Ggg ggggggg ggggggggg cacttatca aacaaacaaaacaa aaatcttacaat aatttc 6240
gggggggggggggg atattataa ttttttcaa accaatta cactccaa taaatt caacac 6180 Ggggggggggggggg atattataa ttttttcaa accaatta cactccaa taaatt caacac 6180
gg gggg gggggggg tatccaaatctacaaaataca accaccc taatacttc ttttacaca 6120 Gg gggg gggggggg tatccaaatctacaaaataca accaccc taatacttc ttttacaca 6120
ggggg ggggg ggg atcccaact taatctaa ttttttacaactataa attacatttaaaaa 6060 Ggggg ggggg ggg atcccaact taatctaa ttttttacaactataa attacatttaaaaa 6060
g ggggggggggg accaccatccatatcc tacctaat catta cactcactt 6000 g ggggggggggg accaccatccatatcc tacctaat catta cactcactt 6000
gggggggg ggggg acttctc aatttcaa aaactttc attttataataaa 5940 Gggggggg ggggg acttctc aatttcaa aaactttc attttataataaa 5940
ggggg gggggggg ccaataca taaaatac aaactattcaataa attattact ctaatcta 5880 Ggggg gggggggg ccaataca taaaatac aaactattcaataa attattact ctaatcta 5880
gggggggggggg ttttaac acccaatc accaacac tcccaaat tctcattca ccataaca 5820 Gggggggggggg ttttaac acccaatc accaacac tcccaaat tctcattca ccataaca 5820
ggggggggggggggggggg ctaacta acatc cttctat tataaac acttcatc aaaacac 5760 Ggggggggggggggggggg ctaacta acatc cttctat tataaac acttcatc aaaacac 5760
ggg ggggggggg gg attattccactct aacccaaac tatcacaca acaattcataatcta 5700 Ggg ggggggggg gg attattccactct aacccaaac tatcacaca acaattcataatcta 5700
gggggg gggggggg ataaaaata aaaatataactcc cctcaaaa atttcaa aaaataaaa 5640 Gggggg gggggggg ataaaaata aaaatataactcc cctcaaaa atttcaa aaaataaaa 5640
gg ggggggggg tctccccatcttttctc aaaatatt ctattataa taaattt acaaatcc 5580 Gg ggggggggg tctccccatcttttctc aaaatatt ctattataa taaattt acaaatcc 5580
gg gggggggggg ggg acattactatcaaa ctacatca atcctctc cactacactatcata 5520 Gg gggggggggg ggg acattactatcaaa ctacatca atcctctc cactacactatcata 5520
gggggggggggggg ttaaaacac ccacttca aataaac tctacctta ctacctca aacca 5460 Ggggggggggggg ttaaaacac ccacttca aataaac tctacctta ctacctca aacca 5460
ggggggggggggggg gg taaaat taaat ataaaaaac ttccca aatccttaaaacaccca 5400 Ggggggggggggggg gg taaaat taaat ataaaaaac ttccca aatccttaaaacaccca 5400
ggggggggggg gggggggg tcaatc ccaaaac caaactaccc aaaacaaaaacat aaaaa 5340 Ggggggggggg gggggggg tcaatc ccaaaac caaactaccc aaaacaaaaacat aaaaa 5340
ggg ggg ggggggggggg ttaatctataactctcaaataa taaca taaccca aatatctta 5280 Ggg ggg ggggggggggg ttaatctataactctcaaataa taaca taaccca aatatctta 5280
ggg ggggggggggg acacacat cctaatcttcatacc cactatcaa aaaaata ctcaacc 5220 Ggg ggggggggggg acacacat cctaatcttcatacc cactatcaa aaaaata ctcaacc 5220
ggggggggggggg gg ctctcacctt taaaac atccaaaa cacaatttc tccaacatcttc 5160 Ggggggggggggg gg ctctcacctt taaaac atccaaaa cacaatttc tccaacatcttc 5160
ggggg gg ggggg attttcttaatccata tttccaaccaacttcatcattatc catatact 5100 Ggggg gg ggggg attttcttaatccata tttccaaccaacttcatcattatc catatact 5100
gggggggg ggg gggggggcttcaa aaaactatc aatatccaacaacaataaa acaatcct 5040 Gggggggg ggg gggggggcttcaa aaaactatc aatatccaacaacaataaa acaatcct 5040
gggggggggg ggggggg atctcttca cacaaatc ataaacac tcaaac ccatatacaatc 4980 Gggggggggg ggggggg atctcttca cacaaatc ataaacac tcaaac ccatatacaatc 4980
ggg ggggggggggg tcacccttactttttaaataaa tattaaa accttaaa acttacctc 4920 Ggg ggggggggggg tcacccttactttttaaataaa tattaaa accttaaa acttacctc 4920
g ggg gggggggggg gg tt aaaacaaacttcctacaata aaacaa cattcttaacatttcc 4860 g ggg gggggggggg gg tt aaaacaaacttcctacaata aaacaa cattcttaacatttcc 4860
gggggg ggggggggggcataatccttc aaccatccc taacta tcacatctc ctaaaatca 4800 Gggggg ggggggggggcataatccttc aaccatccc taacta tcacatctc ctaaaatca 4800
gggggggg gg taaacact caaaaaac aattaat tttcactctttaaatca 4740 Ggggggggg gg taaacact caaaaaac aattaat tttcactctttaaatca 4740
gggg gggggg gggggg ctaacaaaaaact atctacc tcctcttcaaacaacc aaattacc 4680 ggggggggg ggg gg ataacact caccaatc aaatactca caaaataaaaccacattcctt 4620 ccgcttggaa taaggccggt gtgcgtttgt ctatatgtga ttttccacca tattgccgtc 7260 Gggg gggggg gggggg ctaacaaaaaact atctacc tcctcttcaaacaacc aaattacc 4680 ggggggggg ggg gg ataacact caccaatc aaatactca caaaataaaaccacattcctt 4620 Ccgcttggaa taaggccggt gtgcgtttgt ctatatgtga ttttccacca tattgccgtc 7260
ttttggcaat gtgagggccc ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg 7320 Ttttggcaat gtgagggccc ggaaacctgg ccctgtcttc ttgacgagca ttcctagggg 7320
tctttcccct ctcgccaaag gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc 7380 Tctttcccct ctcgccaaag gaatgcaagg tctgttgaat gtcgtgaagg aagcagttcc 7380
tctggaagct tcttgaagac aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc 7440 Tctggaagct tcttgaagac aaacaacgtc tgtagcgacc ctttgcaggc agcggaaccc 7440
cccacctggc gacaggtgcc tctgcggcca aaagccacgt gtataagata cacctgcaaa 7500 Cccacctggc gacaggtgcc tctgcggcca aaagccacgt gtataagata cacctgcaaa 7500
ggcggcacaa ccccagtgcc acgttgtgag ttggatagtt gtggaaagag tcaaatggct 7560 Ggcggcacaa ccccagtgcc acgttgtgag ttggatagtt gtggaaagag tcaaatggct 7560
ctcctcaagc gtattcaaca aggggctgaa ggatgcccag aaggtacccc attgtatggg 7620 Ctcctcaagc gtattcaaca aggggctgaa ggatgcccag aaggtacccc attgtatggg 7620
atctgatctg gggcctcggt gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg 7680 Atctgatctg gggcctcggt gcacatgctt tacatgtgtt tagtcgaggt taaaaaaacg 7680
tctaggcccc ccgaaccacg gggacgtggt tttcctttga aaaacacgat gataagctag 7740 Tctaggcccc ccgaaccacg gggacgtggt tttcctttga aaaacacgat gataagctag 7740
ctcgagcacg tgttgacaat taatcatcgg catagtatat cggcatagta taatacgaca 7800 Ctcgagcacg tgttgacaat taatcatcgg catagtatat cggcatagta taatacgaca 7800
aggtgaggaa ctaaaccatg gccaagcctt tgtctcaaga agaatccacc ctcattgaaa 7860 Aggtgaggaa ctaaaccatg gccaagcctt tgtctcaaga agaatccacc ctcattgaaa 7860
gagcaacggc ~ acaat caac agcatcccca tctctgaaga ctacagcgtc gccagcgcag 7920 Gagcaacggc ~ acaat caac agcatcccca tctctgaaga ctacagcgtc gccagcgcag 7920
ctctctctag cgacggccgc atcttcactg gtgtcaatgt atatcatttt actgggggac 7980 Ctctctctag cgacggccgc atcttcactg gtgtcaatgt atatcatttt actgggggac 7980
cttgtgcaga actcgtggtg ctgggcactg ctgctgctgc ggcagctggc aacctgactt 8040 Cttgtgcaga actcgtggtg ctgggcactg ctgctgctgc ggcagctggc aacctgactt 8040
gtatcgtcgc gatcggaaat gagaacaggg gcatcttgag cccctgcgga cggtgccgac 8100 Gtatcgtcgc gatcggaaat gagaacaggg gcatcttgag cccctgcgga cggtgccgac 8100
aggtgcttct cgatctgcat cctgggatca aagccatagt gaaggacagt gatggacagc 8160 Aggtgcttct cgatctgcat cctgggatca aagccatagt gaaggacagt gatggacagc 8160
<210> 3 <210> 3
<211> 20 <211> 20
<212> DNA <212> DNA
<213> 人工序列 <213> Artificial sequence
<400> 3 <400> 3
aatacggtta tccacgcggc 20 Aatacggtta tccacgcggc 20
<210> 4 <210> 4
<211> 66 <211> 66
<212> DNA <212> DNA
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310751755.0A CN103668472B (en) | 2013-12-31 | 2013-12-31 | Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system |
| CN201310751755.0 | 2013-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015100929A1 true WO2015100929A1 (en) | 2015-07-09 |
Family
ID=50307222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2014/078586 Ceased WO2015100929A1 (en) | 2013-12-31 | 2014-05-28 | Method for constructing eukaryotic gene knockout library by using crispr/cas9 system |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103668472B (en) |
| WO (1) | WO2015100929A1 (en) |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
| US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2018020050A1 (en) * | 2016-07-29 | 2018-02-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Targeted in situ protein diversification by site directed dna cleavage and repair |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| WO2018236079A1 (en) * | 2017-06-19 | 2018-12-27 | 서울대학교병원 | Liver fibrosis induction vector and method for manufacturing animal model using the same |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10227581B2 (en) | 2013-08-22 | 2019-03-12 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US10669539B2 (en) | 2016-10-06 | 2020-06-02 | Pioneer Biolabs, Llc | Methods and compositions for generating CRISPR guide RNA libraries |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| EP3816292A4 (en) * | 2018-07-04 | 2022-01-05 | Guangdong Sanjie Forage Biotechnology Co., Ltd | PROCESS FOR OBTAINING MULTI-LEAF ALFALFAMATERIAL USING ARTIFICIAL SITUATED MSPALM1 MUTANT |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| CN110872583A (en) | 2012-12-12 | 2020-03-10 | 布罗德研究所有限公司 | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| CN113425857B (en) | 2013-06-17 | 2025-05-16 | 布罗德研究所有限公司 | Delivery and use of CRISPR-Cas systems, vectors and compositions for liver targeting and treatment |
| CN105793425B (en) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components |
| EP3011029B1 (en) | 2013-06-17 | 2019-12-11 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| EP4245853A3 (en) | 2013-06-17 | 2023-10-18 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| CN111206032B (en) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for genome editing |
| MX2016007325A (en) | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders. |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| SG10201804975PA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders |
| JP6793547B2 (en) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | Optimization Function Systems, methods and compositions for sequence manipulation with the CRISPR-Cas system |
| CN103668472B (en) * | 2013-12-31 | 2014-12-24 | 北京大学 | Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system |
| CN103911376B (en) * | 2014-04-03 | 2017-02-15 | 黄行许 | CRISPR-Cas9 targeted knockout hepatitis b virus cccDNA and specific sgRNA thereof |
| CN103981216B (en) * | 2014-05-23 | 2016-06-22 | 安徽省农业科学院水稻研究所 | A kind of key plasmid vector and application |
| CN104178512B (en) * | 2014-05-30 | 2017-07-21 | 广州辉园苑医药科技有限公司 | A kind of androgen receptor gene knocks out kit |
| CA3176503A1 (en) * | 2014-07-21 | 2016-01-28 | Illumina, Inc | Polynucleotide enrichment using crispr-cas systems |
| WO2016058171A1 (en) * | 2014-10-17 | 2016-04-21 | Shanghai Sidansai Biotechnology Co.,Ltd | Method for directional cloning |
| CN104450774A (en) * | 2014-12-04 | 2015-03-25 | 中国农业科学院作物科学研究所 | Construction of soybean CRISPR/Cas9 system and application of soybean CRISPR/Cas9 system in soybean gene modification |
| EP3230451B1 (en) | 2014-12-12 | 2021-04-07 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| CN104560864B (en) * | 2014-12-22 | 2017-08-11 | 中国科学院微生物研究所 | Utilize the 293T cell lines of the knockout IFN β genes of CRISPR Cas9 system constructings |
| CA2970370A1 (en) | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
| SG10201906070XA (en) | 2014-12-31 | 2019-08-27 | Synthetic Genomics Inc | Compositions and methods for high efficiency in vivo genome editing |
| WO2016187904A1 (en) * | 2015-05-22 | 2016-12-01 | 深圳市第二人民医院 | Method for pig cmah gene specific knockout by means of crispr-cas9 and sgrna for specially targeting cmah gene |
| CN104894071A (en) * | 2015-06-08 | 2015-09-09 | 东华大学 | Method for carrying out gene edition on GT1-7 cells |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| JP7107683B2 (en) | 2015-06-18 | 2022-07-27 | ザ・ブロード・インスティテュート・インコーポレイテッド | CRISPR enzyme mutations that reduce off-target effects |
| CN106399361A (en) * | 2015-07-30 | 2017-02-15 | 聂凌云 | Method for screening mitochondria genome editing tool targeting target sequence |
| CN105567692B (en) * | 2016-02-26 | 2018-08-14 | 浙江大学 | A kind of sgRNA of selectively targeted QKI genes and its application |
| CN107513538A (en) * | 2016-06-17 | 2017-12-26 | 北京大学 | Gene knockout method |
| CN107784200B (en) * | 2016-08-26 | 2020-11-06 | 深圳华大生命科学研究院 | Method and device for screening novel CRISPR-Cas system |
| CN106399377A (en) * | 2016-09-07 | 2017-02-15 | 同济大学 | Method for screening drug target genes based on CRISPR/Cas9 high-throughput technology |
| CN106637421B (en) * | 2016-10-28 | 2019-12-27 | 博雅缉因(北京)生物科技有限公司 | Construction of double sgRNA library and method for applying double sgRNA library to high-throughput functional screening research |
| US20230183884A1 (en) * | 2016-11-30 | 2023-06-15 | China Agricultural University | A method for crispr library screening |
| CN106755026A (en) * | 2016-12-18 | 2017-05-31 | 吉林大学 | The foundation of the structure and enamel hypocalcification model of sgRNA expression vectors |
| CN106978399A (en) * | 2017-02-16 | 2017-07-25 | 华中农业大学 | The mouse macrophage and construction method of nlrp3 gene knockouts |
| CN106939317A (en) * | 2017-03-24 | 2017-07-11 | 华南农业大学 | It is a kind of to improve the method that plant resists the ability of RNA virus |
| CN108728476A (en) * | 2017-04-14 | 2018-11-02 | 复旦大学 | A method of generating diversity antibody library using CRISPR systems |
| CN107099850B (en) * | 2017-06-19 | 2018-05-04 | 东北农业大学 | A kind of method that CRISPR/Cas9 genomic knockouts library is built by digestion genome |
| CN107236763A (en) * | 2017-06-26 | 2017-10-10 | 中南民族大学 | A kind of method for building Knockout cells system based on flow cytometry |
| CN109207515A (en) | 2017-07-03 | 2019-01-15 | 华中农业大学 | A method of design and building pig full-length genome CRISPR/Cas9 knock out library |
| WO2019024081A1 (en) | 2017-08-04 | 2019-02-07 | 北京大学 | Tale rvd specifically recognizing dna base modified by methylation and application thereof |
| US11624077B2 (en) | 2017-08-08 | 2023-04-11 | Peking University | Gene knockout method |
| CN109385421A (en) * | 2017-08-08 | 2019-02-26 | 北京大学 | Gene knockout method |
| CN108148866B (en) * | 2018-01-19 | 2020-09-01 | 中国人民解放军第三0二医院 | HCBP6 gene knockout cell line and construction method thereof |
| CN110373430B (en) * | 2018-04-13 | 2021-02-19 | 青岛清原化合物有限公司 | Random mutation gene editing system and application thereof |
| JP7641233B2 (en) * | 2019-04-12 | 2025-03-06 | アストラゼネカ・アクチエボラーグ | Compositions and methods for improved gene editing |
| CN113122578A (en) * | 2019-12-30 | 2021-07-16 | 博雅缉因(北京)生物科技有限公司 | Electric shock transformation method for efficiently constructing cell library |
| CN111549052A (en) * | 2020-05-07 | 2020-08-18 | 西南大学 | Eukaryotic organism CRISPR/Cas whole genome editing vector library and construction method |
| CN117587013B (en) * | 2023-11-27 | 2024-06-14 | 湖南师范大学 | Construction method of zebra fish model for vascular dysplasia |
| CN119193789B (en) * | 2024-09-30 | 2025-06-20 | 北京大学 | A method combining spatial transcriptome and CRISPR screening in an unbiased manner and its application in gene function verification |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013141680A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| CN103668472A (en) * | 2013-12-31 | 2014-03-26 | 北京大学 | Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system |
-
2013
- 2013-12-31 CN CN201310751755.0A patent/CN103668472B/en active Active
-
2014
- 2014-05-28 WO PCT/CN2014/078586 patent/WO2015100929A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013141680A1 (en) * | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| CN103668472A (en) * | 2013-12-31 | 2014-03-26 | 北京大学 | Method for constructing eukaryon gene knockout library by using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system |
Non-Patent Citations (2)
| Title |
|---|
| CHO, S.W. ET AL.: "Heritable Gene Knockout in Caenorhabditis elegans by Direct Injection of Cas9-sgRNA Ribonucleoproteins", GENETICS, vol. 195, 30 November 2013 (2013-11-30), pages 1177 - 1180 * |
| MIAO, J. ET AL.: "Targeted mutagenesis in rice using CRISPR-Cas system", CELL RES, vol. 23, no. 10, 3 September 2013 (2013-09-03), pages 1233 - 1236 * |
Cited By (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
| US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
| US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
| US10227581B2 (en) | 2013-08-22 | 2019-03-12 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
| US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
| US12473573B2 (en) | 2013-09-06 | 2025-11-18 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
| US10190137B2 (en) | 2013-11-07 | 2019-01-29 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
| US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
| US10640788B2 (en) | 2013-11-07 | 2020-05-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAs |
| US11390887B2 (en) | 2013-11-07 | 2022-07-19 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US12215365B2 (en) | 2013-12-12 | 2025-02-04 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US12398406B2 (en) | 2014-07-30 | 2025-08-26 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| US12344869B2 (en) | 2015-10-23 | 2025-07-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3219799A1 (en) | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
| WO2017158153A1 (en) | 2016-03-17 | 2017-09-21 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Conditional crispr sgrna expression |
| WO2018020050A1 (en) * | 2016-07-29 | 2018-02-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Targeted in situ protein diversification by site directed dna cleavage and repair |
| US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US10669539B2 (en) | 2016-10-06 | 2020-06-02 | Pioneer Biolabs, Llc | Methods and compositions for generating CRISPR guide RNA libraries |
| US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US12435331B2 (en) | 2017-03-10 | 2025-10-07 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2018236079A1 (en) * | 2017-06-19 | 2018-12-27 | 서울대학교병원 | Liver fibrosis induction vector and method for manufacturing animal model using the same |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US12359218B2 (en) | 2017-07-28 | 2025-07-15 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3816292A4 (en) * | 2018-07-04 | 2022-01-05 | Guangdong Sanjie Forage Biotechnology Co., Ltd | PROCESS FOR OBTAINING MULTI-LEAF ALFALFAMATERIAL USING ARTIFICIAL SITUATED MSPALM1 MUTANT |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US12281303B2 (en) | 2019-03-19 | 2025-04-22 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103668472B (en) | 2014-12-24 |
| CN103668472A (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015100929A1 (en) | Method for constructing eukaryotic gene knockout library by using crispr/cas9 system | |
| CN114269919B (en) | Targeted RNA editing with engineered RNA using endogenous ADAR | |
| CN110295149B (en) | A mutant strain type 3 duck hepatitis A virus CH-P60-117C strain and construction method | |
| KR20230045612A (en) | KRAB fusion inhibitors and methods and compositions for inhibiting gene expression | |
| CN117015605A (en) | Targeted RNA editing using engineered RNAs by utilizing endogenous ADAR | |
| Guan et al. | RNA targeting with CRISPR-Cas13a facilitates bacteriophage genome engineering | |
| CN109055375B (en) | Method for activating gene expression by CRISPR (clustered regularly interspaced short palindromic repeats) auxiliary trans-enhancer and application of method | |
| CN114350615B (en) | STAT2 gene deletion cell strain and preparation method and application thereof | |
| CN113549656A (en) | Lentiviral vector expression system for polygene transformation | |
| CN108949794B (en) | A kind of TALE expression vector and its rapid construction method and application | |
| CN101260408B (en) | Construction method and application of two-color fluorescence report carrier | |
| CN109321571A (en) | A method of utilizing CRISPR/Cas9 preparation and reorganization porcine pseudorabies virus | |
| CN114369619A (en) | Reporter vector and vector system for gene knockout and application | |
| CN112029736A (en) | Recombinant pseudorabies live vaccine for preventing African swine fever and preparation method thereof | |
| CN109371167A (en) | Genetic elements and the application of frameshift mutation are generated for detecting CRISPR/Cas9 gene editing system cutting gene | |
| CN114395017B (en) | Preparation method and application of SARS-CoV-2 virus-like particle | |
| CN110295180B (en) | Type 3 duck hepatitis A virus mutant gene ISA-A117C-C4334A and construction method thereof | |
| CN110684781B (en) | A kind of type 3 duck hepatitis A virus mutant gene ISA-A117C-T1142A and construction method | |
| CN114395579B (en) | Gene I and gene III Japanese encephalitis virus infectious clone and construction method and application thereof | |
| CN101186925B (en) | Universal high-efficiency eukaryotic expression vector p3I-GFPN and anti-mastitis transgene vector constructed by using the vector | |
| CN103131709B (en) | Ribonucleic acid (RNA) interference fragment of zinc finger-x (zfx) gene and application of RNA interference fragment in mouse sex control | |
| CN110283835B (en) | Type 3 duck hepatitis A virus mutant gene ISA-T1142A-C4334A and construction method | |
| CN113652406B (en) | Recombinant virus strain for infectious laryngotracheitis of chickens and application thereof | |
| CN110484546B (en) | Type-3 duck hepatitis A virus mutant gene ISA-C4334A and construction method | |
| CN104195153A (en) | Bicistronic co-expression gene transfer bodyand preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14876418 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205N DATED 12-10-2016 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14876418 Country of ref document: EP Kind code of ref document: A1 |